IL6 and systemic sclerosis: found that incubation with etoposide, a carnitine transporter inhibitor, restrained fatty acid oxidation and suppressed the production of pro-inflammatory cytokines such as IL-6, revealing an altered metabolic state of the immune system in SSc patients and opening up new avenues of a potential treatment for the alleviation of inflammation (27).